1. Introduction {#s0005}
===============

The ongoing coronavirus disease pandemic (COVID-19) poses a great challenge to healthcare systems worldwide. Beyond challenges for direct patient care, optimal conduct of research under the specific conditions of the pandemic is a matter of concern and discussion. We present the *meta-trial* concept as a scientifically, clinically, ethically and socially sound method to carry out optimal clinical research in the setting of a pandemic. We take the example of such a *meta-trial*, set up to investigate prone positioning among awake patients undergoing nasal high flow therapy and invite journal readers to join this collaborative research effort.

2. COVID-19 constraints to clinical research {#s0010}
============================================

The pandemic has placed the research community under great pressure with the urgent need for results, given the lack of knowledge concerning optimal management of patients suffering this new disease. Public pressure is high due to the lack of specific effective therapy regarding this major threat to public health; the traditional pace of clinical research being considered as not adapted by most stakeholders. Worldwide funding agencies and regulatory bodies changed their procedures in order to speed up the research process. This effort has led to the launch of a high number of clinical studies within a short period of time to an unprecedented extent. As of 2020 June 15th, 2138 COVID-19 trials were registered in [clinicaltrials.gov](http://clinicaltrials.gov){#ir0010}.

3. Pros/cons of national independent trials vs international trials {#s0015}
===================================================================

Numerous such trials launched simultaneously across hospitals in various countries address similar research questions. E.g. the search terms of "COVID AND Prone" to retrieve studies evaluating patient prone positioning on [clinicaltrials.gov](http://clinicaltrials.gov){#ir0015} yielded 6, 31 and 44 results on the 5th of April, 5th of May and 5th of June respectively. This poses a major risk of redundant work, poor research resource allocation and incompletion of some trials -- this happened all too often during previous epidemics \[[@bb0005], [@bb0010], [@bb0015]\]. Researchers may waste time writing protocols from scratch while others already obtained funding or regulatory approvals. Although data generated by these numerous trials may ultimately be meta-analyzed, the time required for these numerous individual trials to publish and then compile data may be incompatible with the pressure of the epidemic. Several stakeholders called for a coordinated research effort, which should ideally take place at the international level \[[@bb0005]\].

However, setting up an international trial requires tremendous resources and time to finalize a unique protocol translated in various languages, coordinate all regulatory and ethical approvals, and conduct trials and data quality assessment in each country \[[@bb0020],[@bb0025]\]. Such efforts have been conducted successfully for observational studies with the support of international research networks and scientific societies \[[@bb0030]\]. However, the hurdles to set up a large scale international interventional randomized controlled trial are incompatible with the resources of an academic sponsor and are thus often restricted to pharmaceutical companies. When evaluating non-pharmacological interventions such as prone positioning, which has been proven to reduce mortality in mechanically ventilated patients with ARDS \[[@bb0035]\], the lack of foreseeable return on investment precludes such funding.

4. The *meta-trial* as a pragmatic solution for efficient pandemic clinical research {#s0020}
====================================================================================

In order to combine the benefits of international research with the fast setup of national trials, we propose to coordinate multiple national investigator-initiated trials in the form of a prospective meta-analysis. This so-called "*meta-trial*" consists of aggregating data from various national trials during the data collection \[[@bb0040]\]. To study prone positioning in awake patients with COVID-19 pneumonia, two such trials were registered on [clincaltrials.gov](http://clincaltrials.gov){#ir0020} (one in the USA, the other in France) in mid-march 2020, and the investigators got in contact with 3 other groups planning trials with very similar inclusion and outcome criteria in Canada, Ireland and Spain, who all joined the *meta-trial* project. Each trial could be set up within a few weeks given the accelerated procedures in place during the COVID-19 outbreak. Planned sample sizes of individual trials ranged from 198 to 346 patients with the total planned inclusion of 1386 patients across 5 countries. Investigators and methodologists of all groups organized several web meetings to harmonize inclusion criteria and primary and secondary outcomes of the *meta-trial*. Given the planned sample sizes, an interim analysis plan was developed at the *meta-trial* level analyzing aggregated data every 200 patients. A memorandum of understanding and data sharing agreement were drafted (available upon request).

The *meta-trial* concept enables researchers to combine the agility of smaller national trials into a much larger international project in a short period of time ([Table 1](#t0005){ref-type="table"} ). *Meta-trial* interim analysis enables to detect a positive or negative response to the scientific question as soon as an adequate sample size is reached across several countries, thus potentially speeding up the research process dramatically \[[@bb0045],[@bb0050]\]. Adherence to methodological standards of individual trials represents a guarantee of a high level of overall final quality. Furthermore, by estimating the treatment effect across the various trials upfront, the *meta-trial* may provide stronger evidence in favor of external validity and replicability of the individual trials.Table 1Comparison of the meta-trial concept to alternative designs.Table 1Individual trials followed by a retrospective meta-analysisInternational single trial*Meta-trial*: prospective international meta-analysisEligibility criteria for participantsHeterogenous between trialsUniform within the trialSimilar between trials (may have some heterogeneity within clinical relevance)Baseline dataHeterogenous between trialsUniform within the trialCommon set of variables in data sharing agreementIntervention details and how they were administeredHeterogenous between trialsUniform within the trialUniform between trials: agreement between individual investigators to deliver same interventionPre-specified primary and secondary outcome measuresHeterogenous between trialsUniform within the trialUniform between trials (investigators agree on a common set of outcomes)Samples size and Interim analysisHeterogenous between trials, interim analyses impossible at the meta-levelOne sample size calculation for the trial, interim analyses possibleMeta-trial design transcends original sample size calculation, interim analyses possible at the meta-levelRandomization- sequence generation, stratification, allocation sequence, concealment and blindingHeterogenous between trialsCentralized randomizationMay differ for each site but fundamental randomization principles adhered toStatistical methodsHeterogenous original analyses, meta-analysis on effect sizes to compute a summary effectUniform within the trial, adjustments possibleUniform within the trials, meta-analysis on individual participant data, adjustments possibleAnalysis populations: intention to treat, Per protocol, subgroupsHeterogenous between studiesUniform within the trialUniform between the trials (agreement on uniform analysis population)Data quality and safety monitoringEach trialist is responsible for his or her trialCentralized data monitoringEach trialist is responsible for his or her trialFundingMultiple fundingCentralized fundingMultiple fundingSet-up timeShortLongShortTime to completionLongShortShortProtocolsMultiple original protocolsOneMultiple original protocols followed by a meta-trial protocolEthicsEach trialist is responsible for his or her trialCentralized submission processEach trialist is responsible for his or her trial

To the best of our knowledge, the *meta-trial* concept has never been experienced in real life across several countries, and feasibility uncertainties do exist. The present project may serve as a guidance for future research projects set up in a pandemic context.

5. How to join {#s0025}
==============

The *meta-trial* is a living project in the sense that other groups can join as long as they adhere to the general principle and abide by ethical regulations in their country. Protocols and clinical record files are made available upon request by the core investigator group of the *meta-trial*. Readers are invited to contact authors for any additional information and to join the project (<Awake.Prone.Meta.Trial@gmail.com>).
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